## Check for updates

## **OPEN ACCESS**

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

\*CORRESPONDENCE Frontiers Production Office, production.office@frontiersin.org

RECEIVED 26 November 2024 ACCEPTED 26 November 2024 PUBLISHED 09 December 2024

### CITATION

Frontiers Production Office (2024) Erratum: Feasibility exploration of GSH in the treatment of acute hepatic encephalopathy from the aspects of pharmacokinetics, pharmacodynamics, and mechanism. *Front. Pharmacol.* 15:1534991. doi: 10.3389/fphar.2024.1534991

#### COPYRIGHT

© 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Erratum: Feasibility exploration of GSH in the treatment of acute hepatic encephalopathy from the aspects of pharmacokinetics, pharmacodynamics, and mechanism

## Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

### KEYWORDS

glutathione, acute hepatic encephalopathy, oxidative stress, endoplasmic reticulum stress, iNOS/ATF4/Ddit3

### An Erratum on

Feasibility exploration of GSH in the treatment of acute hepatic encephalopathy from the aspects of pharmacokinetics, pharmacodynamics, and mechanism

by Hu K, Xu Y, Fan J, Liu H, Di C, Xu F, Wu L, Ding K, Zhang T, Wang L, Ai H, Xie L, Wang G and Liang Y (2024). Front. Pharmacol. 15:1387409. doi: 10.3389/fphar.2024.1387409

Due to a production error, an incorrect number was provided for "the National Natural Science Foundation of China". The correct number is 82274194.

The publisher apologizes for this mistake. The original version of this article has been updated.